Related Experiment Video
Updated: Feb 19, 2026
07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
15.3K
Lingual alveolar soft part sarcoma responsive to pazopanib: A case report
Tomoyasu Yoshihiro1, Kenji Tsuchihashi, Kenta Nio
1Department of Hematology, Oncology and Cardiovascular medicine Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences Department of Otorhinolaryngology Department of Anatomical Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Medicine
|November 3, 2017
Summary
Pazopanib showed temporary efficacy in a rare case of lingual alveolar soft part sarcoma (ASPS) with metastasis. Further research is needed to establish optimal therapies for this rare cancer.
Area of Science:
- Oncology
- Rare Cancers
Background:
- Alveolar soft part sarcoma (ASPS) is a rare malignancy.
- Multi-targeted tyrosine kinase inhibitors (TKIs) show promise for ASPS treatment.
- The efficacy of pazopanib in lingual ASPS remains largely unreported.
Observation:
- A 23-year-old male presented with tongue swelling and articulation difficulties, diagnosed as lingual ASPS.
- The patient developed a mental region mass and lung metastasis after initial treatment.
- Initial combination chemotherapy with doxorubicin and ifosfamide failed.
Findings:
- Pazopanib administration resulted in temporary shrinkage of both the mental region and lung metastases.
- Tumor regrowth was observed after four months of pazopanib treatment.
- Lingual ASPS presents unique characteristics distinct from conventional ASPS.
Implications:
- Pazopanib may offer a potential therapeutic strategy for lingual ASPS.
- Optimal treatment protocols for lingual ASPS require further investigation.
- This case highlights the challenges in managing rare metastatic sarcomas.
